

1

## Supporting Information

2 **Simultaneous on-site visual identification of norovirus GI and GII**

3 **genogroups with point-of-care molecular lateral flow strip**

4 Ziwen Zong<sup>1</sup>, Xianzhuo Meng<sup>1</sup>, Weiwei Li<sup>2</sup>, Jianguo Xu<sup>1</sup>, Junling Yu<sup>2</sup>, Xinxin Wang<sup>2</sup>,

5 Peng Wang<sup>2</sup>, Guodong Liu<sup>3</sup>, Yong Sun<sup>2,\*</sup>, Wei Chen<sup>1,\*</sup>

6 <sup>1</sup>Engineering Research Center of Bio-process, MOE, School of Food and Biological  
7 Engineering, Hefei University of Technology, Hefei 230009, P. R. China

8 <sup>2</sup>Center of Disease Control and Prevention of Anhui Province, Hefei, 230009, China

9 <sup>3</sup>School of Chemistry and Chemical Engineering, Linyi University, Linyi, 276005,  
10 China

11

---


\* Corresponding email: chenweishnu@163.com (W. C., ORCID: 0000-0003-3763-1183)

12 **Table S1.** The sequence and functionalization information of primer sets

Name	Primer	Sequence	Product size
NoV GI	GI-F	5'-FITC-CTGCCCCGAATTYGTAATGA-3'	330 bp
	GI-R	5'-Biotin-CCAACCCARCCATTRTACA-3'	
NoV GII	GII-F	5'-Dig-TGAGATTCTCAGATCTGAGCACGTGGGA-3'	132 bp
	GII-R	5'-FITC-ATTATTGACCTCTGGGACGAGGTTGGCT-3'	

13

14



15

16 **Fig. S1** Characterization of AuNPs. AuNPs of wine red in a glass bottle, and TEM image (20 nm


17 and 5 nm) of AuNPs.

## 18 Optimization of experimental conditions of mPCR and LFS

19 To ensure efficient nucleic acid amplification, annealing and extension steps were performed  
20 at different temperatures. **Fig. S2A** and **Fig. S2B** demonstrate that amplification efficiency gradually  
21 increases with increasing annealing temperature, but is significantly inhibited beyond a certain  
22 point. Similarly, for extension temperatures, short fragment product extension becomes less  
23 favorable at higher temperatures (**Fig. S2C, S2D**). After combining these results with signal  
24 intensity of T lines (**Fig. S4A, S4B**), 54°C was chosen as the optimal anneal temperature and 66°C  
25 for extension. Different primer concentrations were used to investigate the effect on amplification  
26 efficiency. Increasing the NoV GI primer set slightly suppressed the amplification efficiency of  
27 NoV GII, while increasing the NoV GII primer set resulted in a gradual suppression of NoV GI  
28 (**Fig. S3A, S3C**). **Fig. S3B** and **Fig. S3D** showed the effect of different primer concentrations on  
29 the determination of results from the perspective of LFS visual detection. **Fig. S4C** and **Fig. S4D**  
30 showed the change of T-line signal intensity with primer concentration. Considering the need for  
31 simultaneous identification of GI and GII genogroups of norovirus, the optimal primer concentration  
32 for both was determined to be 240 nM. These conditions ensure that both genogroups can be  
33 adequately amplified with balanced competition between each other.

34 To ensure the consistency of amplification results with corresponding LFS visualization  
35 measurements, we have investigated various parameters that impact the performance of the LFS  
36 assay. These parameters include the amount of AuNP-FITC antibody conjugates present on the  
37 conjugation pad, the quantity of FITC antibody coupled to the surface of gold nanoparticles, as well  
38 as the concentrations of Digoxin antibody and SAV.


39 We conducted experiments to optimize several parameters affecting the performance of the  
40 LFS assay. Firstly, we investigated the impact of the amount of AuNP-FITC antibody conjugates  
41 on the conjugation pad, and found that the signal intensity of the two T lines increased with an  
42 increase in the amount of AuNP-FITC antibody conjugates, before eventually reaching saturation  
43 at 6  $\mu$ L (**Fig. S5A, S6A**). Thus, we selected 6  $\mu$ L as the optimal conjugates amount to ensure  
44 sufficient labeling of the two functional amplicons. Subsequently, we optimized the amount of FITC  
45 antibody coupled to the surface of gold nanoparticles to ensure a high target signal and well-  
46 suppressed background (**Fig. S5B, S6B**), and determined that 10  $\mu$ L resulted in preventing the  
47 wastage of antibody. We selected 10  $\mu$ L of FITC antibody for future assays. Finally, we studied the  
48 amounts of antibody sprayed on the test lines of LFS. While maintaining the SAV of T<sub>1</sub> line at 1.5  
49 mg/mL, an elevation of Digoxin antibody concentration led to excessive adsorption of AuNP-FITC  
50 antibody conjugates on the T<sub>2</sub> line, resulting in weaker signal development intensity of the T<sub>1</sub> line  
51 (**Fig. S5C, S6C**). A Digoxin antibody concentration of 0.8 mg/mL led to a clear visual signal of the  
52 T<sub>1</sub> line, and thus this was selected for further experiments. Interestingly, as the amount of SAV  
53 increased, we observed that the signal intensity of the T<sub>1</sub> line gradually increased (**Fig. S5D, S6D**),  
54 but the expression of the T<sub>2</sub> line was not competitively suppressed. This may be due to the different  
55 antibody and affinity. We selected 2 mg/mL as the optimal concentration for SAV to ensure clear  
56 color rendering intensity of the T<sub>1</sub> line, while minimizing wastage.



57

58 **Fig. S2** Influence of the annealing temperature: Results of agarose gel electrophoresis (A) and LFS  
 59 (B); Influence of the extension temperature: Results of agarose gel electrophoresis (C) and LFS (D).

60




61

62 **Fig. S3** Optimization of NoV GI/GII primer concentration: Results of agarose gel electrophoresis

63 (A) and LFS (B) to increasing concentration of NoV GI primer; Results of agarose gel

64 electrophoresis (C) and LFS (D) to increasing concentration of NoV GII primer.

65




66

67 **Fig. S4** The change of signal intensity with amplification conditions: (A) Annealing temperature;

68 (B) Extension temperature; (C) Increasing concentration of NoV GI primer; (D) Increasing

69 concentration of NoV GII primer.

70



71

72 **Fig. S5** Results of optimized LFS conditions: (A) Signal responses of LFS to increasing volume of

73 AuNP-FITC antibody conjugates on the conjugation pad; (B) Signal responses of LFS to increasing


74 volume of FITC antibody; (C) Signal responses of LFS to increasing concentration of Digoxin

75 antibody (Dig-Ab) on the T<sub>2</sub> line; (D) Signal responses of LFS to increasing concentration of SAV

76 on the T<sub>1</sub> line.

77






78

79 **Fig. S6** The change of signal intensity with optimized LFS conditions: (A) Increasing volume of  
 80 AuNP-FITC antibody conjugates on the conjugation pad; (B) Increasing volume of FITC antibody;  
 81 (C) Increasing concentration of Digoxin antibody (Dig-Ab) on the T<sub>2</sub> line; (D) Increasing  
 82 concentration of SAV on the T<sub>1</sub> line.

83




84


85 **Fig. S7** Quantitative analysis of mPCR-LFS for multiple testing of NoV GI and GII. From left to

86 right:  $6 \times 10^0$ ,  $6 \times 10^1$ ,  $6 \times 10^2$ ,  $6 \times 10^3$ ,  $6 \times 10^4$ ,  $6 \times 10^5$ ,  $6 \times 10^6$  copies/reaction (25  $\mu\text{L}$ ).

87



88



89

90 **Fig. S8** The real-time PCR analysis results of the different components in all practical clinical  
 91 samples. (A) Detection of NoV GI component in all clinical samples; (B) Detection of NoV GII  
 92 components in all clinical samples.

93

94 **Table S2** Comparison of recent reported methods for the detection of NoV GI/GII.

No.	Detection methods	Target	LOD	Reference
1	RT-LAMP	NoV GI and GII	10 <sup>2</sup> and 10 <sup>3</sup> copies/μL, NoV GI and GII	1
2	RT-LAMP	NoV GII	10 <sup>3</sup> copies/μL	2
3	Split G-quadruplex	NoV GII	4 nM	3
4	Electrochemical sensor	NoV GII	100 pM	4
6	mPCR-LFS	NoV GI and GII	6 copies/reaction	This study

95

96

97 **Reference**

- 98 1. S. Fukuda, S. Takao, M. Kuwayama, Y. Shimazu and K. Miyazaki, *J. Clin Microbiol*,  
99 2006, **44**, 1376-1381.
- 100 2. J. Luo, Z. Xu, K. Nie, X. Ding, L. Guan, J. Wang, Y. Xian, X. Wu and X. Ma, *Food*,  
101 *Environ. Virol.*, 2014, **6**, 196-201.
- 102 3. K. Nakatsuka, H. Shigeto, A. Kuroda and H. Funabashi, *Biosens. Bioelectron.*, 2015, **74**,  
103 222-226.
- 104 4. R. Chand and S. Neethirajan, *Biosens. Bioelectron.*, 2017, **98**, 47-53.
- 105
- 106